InnoCom Bio Equities, Inc. is a Life Science Investment Manager working with FDA Phase I and II pharmaceutical and therapeutic portfolio companies. It is unique in that it works with companies that have completed their Pre-clinical work and takes them through to its contacts in Big Pharma at Phase III. Along the way, it looks to license future Human products into the Veterinary world, relieving the huge cash drain of the six to eight year program.
InnoCom provides three services: Venture Capital Investment, Infrastructure Development and Maintenance, and Chief Executive Advisory to its twelve existing portfolio companies. It is in the process of adding four for a total of sixteen portfolio companies.
To offset the long incubation period, the returns in Life Science are extraordinarily high: InnoCom’s portion of the returns on its existing portfolio are estimated to be in the $10 to $15 billion range.
Its first fund, InnoCom Bio Equities Fund I, has just completed its $350 million investment and InnoCom is now in the process of completing its licensing for its $300 million Small Business Investment Corporation, InnoCom Bio Equites SBIC, through the Small Business Administration. We have been told by SBA that all is in place for that license with the exception of a track record of successful venture capital exits.
To meet this requirement, InnoCom is offering 2% of its stock ownership of the portfolio companies and fees of $60,000 per year to an additional Director.
A prospective Director needs have only three qualifications:
A strong belief in the market place of ideas
The ability to attend a one half hour meeting per week with his two other fellow Directors
Some five or six substantial venture capital exits
If you meet are interested and meet this criteria, please contact:
Jack E. Doty, Chairman, Co-Founder and CEO
(415) 516-9991